An update on the safety of nutraceuticals and effects on lipid parameters

References

• Bloom DE, Cafiero ET, Jané-Llopis E, et al. The global economic burden of noncommunicable diseases. Geneva: World Economic Forum; 2011 Sep. Report No.: 080911.
   Google Scholar
• Organisation WH. Cardiovascular diseases (CVDs) 2015. [cited 2016 Aug 28]. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/.
   Google Scholar
• Hobbs FD, Banach M, Mikhailidis DP, et al. Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. BMC Med. 2016;14:4.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al.; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
   PubMed Web of Science ®Google Scholar
• Ward N, Sahebkar A, Banach M, et al. Recent perspectives on the role of nutraceuticals as cholesterol-lowering agents. Curr Opin Lipidol. 2017;28(6):495–501.
   PubMed Web of Science ®Google Scholar
• Booth JN 3rd, Colantonio LD, Howard G, et al. Healthy lifestyle factors and incident heart disease and mortality in candidates for primary prevention with statin therapy. Int J Cardiol. 2016;207:196–202.
   PubMed Web of Science ®Google Scholar
• Appel LJ, Sacks FM, Carey VJ, et al.; OmniHeart Collaborative Research Group. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. Jama 2005;294:2455–2464.
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. Biomedicine. Lowering LDL – not only how low, but how long? Science. 2006;311:1721–1731.
   PubMed Web of Science ®Google Scholar
• Brinton EA. Management of hypertriglyceridemia for prevention of atherosclerotic cardiovascular disease. Endocrinol Metab Clin North Am. 2016;45:185–204.
   PubMed Web of Science ®Google Scholar
• Patti AM, Toth PP, Giglio RV, et al. Nutraceuticals as an important part of combination therapy in dyslipidaemia. Curr Pharm Des. 2017 Mar 17;23. doi:10.2174/1381612823666170317145851
   PubMed Web of Science ®Google Scholar
• Houston M. The role of nutraceutical supplements in the treatment of dyslipidemia. J Clin Hypertens. 2012;14:121–132.
   Web of Science ®Google Scholar
• Cicero AF, Fogacci F, Colletti A. Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach. Food Funct. 2017;8:2076–2088.
   PubMed Web of Science ®Google Scholar
• Reiner Ž. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014;24:1057–1066.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al.; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36:1012–1022.
   PubMed Web of Science ®Google Scholar
• Devaraj S, Jialal I. The role of dietary supplementation with plant sterols and stanols in the prevention of cardiovascular disease. Nutr Rev. 2006;64:348–354.
   PubMed Web of Science ®Google Scholar
• Wang P, Chen Y-M, He L-P, et al. Association of natural intake of dietary plant sterols with carotid intima-media thickness and blood lipids in Chinese adults: a cross-section study. PLoS One. 2012;7:e32736.
   PubMed Web of Science ®Google Scholar
• Andersson SW, Skinner J, Ellegård L, et al. Intake of dietary plant sterols is inversely related to serum cholesterol concentration in men and women in the EPIC Norfolk population: a cross-sectional study. Eur J Clin Nutr. 2004;58:1378–1385.
   PubMed Web of Science ®Google Scholar
• Mannarino E, Pirro M, Cortese C, et al. Effects of a phytosterol-enriched dairy product on lipids, sterols and 8-isoprostane in hypercholesterolemic patients: a multicenter Italian study. Nutr Metab Cardiovasc Dis. 2009;19:84–90.
   PubMed Web of Science ®Google Scholar
• Malhotra A, Shafiq N, Arora A, et al. Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia. Cochrane Database Syst Rev. 2014;6:CD001918.
   PubMed Web of Science ®Google Scholar
• Baker WL, Baker EL, Coleman CI. The effect of plant sterols or stanols on lipid parameters in patients with type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2009;84:e33–e37.
   PubMedGoogle Scholar
• Talati R, Sobieraj DM, Makanji SS, et al. The comparative efficacy of plant sterols and stanols on serum lipids: a systematic review and meta-analysis. J Am Diet Assoc. 2010;110:719–726.
   PubMed Web of Science ®Google Scholar
• Brown JM, Yu L. Protein mediators of sterol transport across intestinal brush border membrane. Subcell Biochem. 2010;51:337–380.
   PubMedGoogle Scholar
• Merkens LS, Myrie SB, Steiner RD, et al. Sitosterolemia. 2013 Apr 4. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2017. [Last accessed 2017 Nov 12]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK131810/.
   Google Scholar
• Gylling H, Radhakrishnan R, Miettinen TA. Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine. Circulation. 1997;96:4226–4231.
   PubMed Web of Science ®Google Scholar
• Pirro M, Vetrani C, Bianchi C, et al. Joint position statement on “Nutraceuticals for the treatment of hypercholesterolemia” of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). Nutr Metab Cardiovasc Dis. 2017;27(1):2–17.
   PubMed Web of Science ®Google Scholar
• Brown L, Rosner B, Willett WW, et al. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69:30–42.
   PubMed Web of Science ®Google Scholar
• Marlett JA. Sites and Mechanisms for the Hypocholesterolemic Actions of Soluble Dietary Fiber Sources. In: Kritchevsky D., Bonfield C. (eds) Dietary Fiber in Health and Disease. Advances in Experimental Medicine and Biology, Boston, MA;Springer. 1997;427:109–121.
   Google Scholar
• Wei Z-H, Wang H, Chen X-Y, et al. Time- and dose-dependent effect of psyllium on serum lipids in mild-to-moderate hypercholesterolemia: a meta-analysis of controlled clinical trials. Eur J Clin Nutr. 2009;63(7):821–827.
   PubMed Web of Science ®Google Scholar
• Ribas SA, Cunha DB, Sichieri R, et al. Effects of psyllium on LDL-cholesterol concentrations in Brazilian children and adolescents: a randomised, placebo-controlled, parallel clinical trial. Br J Nutr. 2015;113:134–141.
   PubMed Web of Science ®Google Scholar
• Onakpoya I, Posadzki P, Ernst E. The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. J Am Coll Nutr. 2014;33(1):70–78.
   PubMed Web of Science ®Google Scholar
• Guardamagna O, Abello F, Cagliero P, et al. Could dyslipidemic children benefit from glucomannan intake? Nutrition. 2013;29:1060–1065.
   PubMed Web of Science ®Google Scholar
• Sood N, Baker WL, Coleman CI. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr. 2008;88:1167–1175.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Serban M-C, Gluba-Brzózka A, et al. Lipid-modifying effects of nutraceuticals: an evidence-based approach. Nutrition. 2016;32:1179–1192.
   PubMed Web of Science ®Google Scholar
• Zhu X, Sun X, Wang M, et al. Quantitative assessment of the effects of beta-glucan consumption on serum lipid profile and glucose level in hypercholesterolemic subjects. Nutr Metab Cardiovasc Dis. 2015;25:714–723. 54.
   PubMed Web of Science ®Google Scholar
• Reiner Z, Catapano A, De Backer G, et al. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2011;32:1769–1818.
   PubMed Web of Science ®Google Scholar
• EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on the substantiation of a health claim related to oat beta-glucan and lowering blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA J. 2010;8:188.
   Google Scholar
• Cicero AFG, Colletti A, Bajraktari G, et al. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Arch Med Sci. 2017;13(5):965–1005.
   PubMed Web of Science ®Google Scholar
• Fu J, Bonder MJ, Cenit MC, et al. The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ Res. 2015;117(9):817–824.
   PubMed Web of Science ®Google Scholar
• Garcia-Rios A, Torres-Peña JD, Perez-Jimenez F, et al. Gut microbiota: a new marker of cardiovascular disease. Curr Pharm Des. 2017;23(22):3233–3238.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Hashiguchi M, Shiga T, et al. Meta-analysis: effects of probiotic supplementation on lipid profiles in normal to mildly hypercholesterolemic individuals. PLoS One. 2015;10:e0139795.
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhang Q, Ren Y, et al. Effect of probiotic Lactobacillus on lipid profile: A systematic review and meta-analysis of randomized, controlled trials. PLoS One. 2017;12(6):e0178868.
   PubMed Web of Science ®Google Scholar
• Mistry P. Natural cholesterol-lowering products: focus on probiotics. Br J Community Nurs. 2014;19(Suppl 11):S14–S18.
   Google Scholar
• Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol. 1998;39:237–238.
   PubMed Web of Science ®Google Scholar
• Cho YA, Kim J. Effect of probiotics on blood lipid concentrations: a meta-analysis of randomized controlled trials. Medicine. 2015;94:e1714.
   PubMed Web of Science ®Google Scholar
• Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis (Review). 2015;60 Suppl 2:S129–S134.
   PubMed Web of Science ®Google Scholar
• Gordon RY, Cooperman T, Obermeyer W, et al. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med. 2010;170:1722–1727.
   PubMed Web of Science ®Google Scholar
• Ma J, Li Y, Ye Q, et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem. 2000;48:5220–5225.
   PubMed Web of Science ®Google Scholar
• Gerards MC, Terlou RJ, Yu H, et al. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain – a systematic review and meta-analysis. Atherosclerosis. 2015;240:415–423.
   PubMed Web of Science ®Google Scholar
• Guardamagna O, Abello F, Baracco V, et al. The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr Metab Cardiovasc Dis. 2011 Jun;21(6):424–429.
   PubMed Web of Science ®Google Scholar
• Cicero AF, Morbini M, Rosticci M, et al. Middle-term dietary supplementation with red yeast rice plus coenzyme Q10 improves lipid pattern, endothelial reactivity and arterial stiffness in moderately hypercholesterolemic subjects. Ann Nutr Metab. 2016;68(3):213–219.
   PubMed Web of Science ®Google Scholar
• Mazzanti G, Moro PA, Raschi E, et al. Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. Br J Clin Pharmacol. 2017 Jan 17;83:894–908. [Epub ahead of print]. doi:10.1111/bcp.13171
   PubMed Web of Science ®Google Scholar
• DFG Permanent Senate Commission on Food Safety. Toxicological evaluation of red mould rice: an update. 2012;1–24.
   Google Scholar
• Chan W-H, Shiao N-H. Effect of citrinin on mouse embryonic development in vitro and in vivo. Reprod Toxicol. 2007;24:120–125.
   PubMed Web of Science ®Google Scholar
• Rangboo V, Noroozi M, Zavoshy R, et al. The effect of artichoke leaf extract on alanine aminotransferase and aspartate aminotransferase in the patients with nonalcoholic steatohepatitis. Int J Hepatol. 2016;2016:1–6.
   Google Scholar
• Capasso F, Gaginella TS, Grandolini G, et al. Phytotherapy: a quick reference to herbal medicine. Berlin: Springer; 2003.
   Google Scholar
• Sahebkar A, Pirro M, Banach M, et al. Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2017 Jun 13:1–8. [Epub ahead of print]. doi:10.1080/10408398.2017.1332572
   Google Scholar
• Giglio RV, Patti AM, Nikolic D, et al. The effect of bergamot on dyslipidemia. Phytomedicine. 2016;23:1175–1181.
   PubMed Web of Science ®Google Scholar
• Di Donna L, De Luca G, Mazzotti F, et al. Statin-like principles of bergamot fruit (Citrus bergamia): isolation of 3-hydroxymethylglutaryl flavonoid glycosides. J Nat Prod. 2009;72:1352–1354.
   PubMed Web of Science ®Google Scholar
• Miceli N, Mondello MR, Monforte MT, et al. Hypolipidemic effects of Citrus bergamia Risso et Poiteau juice in rats fed a hypercholesterolemic diet. J Agric Food Chem. 2007;55:10671–10677.
   PubMed Web of Science ®Google Scholar
• Gliozzi M, Walker R, Muscoli S, et al. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. Int J Cardiol. 2013;170:140–145.
   PubMed Web of Science ®Google Scholar
• Gliozzi M, Carresi C, Musolino V, et al. The effect of Bergamot-derived polyphenolic fraction on LDL small dense particles and non alcoholic fatty liver disease in patients with metabolic syndrome. Adv Biol Chem. 2014;4:129–137.
   Google Scholar
• Athyros VG, Tziomalos K, Katsiki N, et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update. World J Gastroenterol. 2015;21:6820–6834.
   PubMed Web of Science ®Google Scholar
• Mollace V, Sacco I, Janda E, et al. Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia. 2011;82:309–316.
   PubMed Web of Science ®Google Scholar
• Ried K, Toben C, Fakler P. Effect on garlic on serum lipids: an updated meta-analysis. Nutr Rev. 2013;71(5):282–299.
   PubMed Web of Science ®Google Scholar
• Steiner M, Lin RS. Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract. J Cardiovasc Pharmacol. 1998;31(6):904–908.
   PubMed Web of Science ®Google Scholar
• Liu C-S, Zheng Y-R, Zhang Y-F, et al. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia. 2016;109:274–282.
   PubMed Web of Science ®Google Scholar
• Abidi P, Zhou Y, Jiang J-D, et al. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol. 2005;25(10):2170–2176.
   PubMed Web of Science ®Google Scholar
• Li H, Dong B, Park SW, et al. Hepatocyte nuclear factor 1α plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound Berberine. J Biol Chem. 2009;284(42):28885–28895.
   PubMed Web of Science ®Google Scholar
• Li XY, Zhao ZX, Huang M, et al. Effect of Berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. J Transl Med. 2015;13:278.
   PubMed Web of Science ®Google Scholar
• Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69–81.
   PubMed Web of Science ®Google Scholar
• Meng S, Wang L-S, Huang Z-Q, et al. Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention. Clin Exp Pharmacol Physiol. 2012;39(5):406–411.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Cicero AF. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther. 2012;12:1113–1124.
   PubMed Web of Science ®Google Scholar
• Xin H-W, Wu X-C, Li Q, et al. The effects of berberine on the pharmacokinetics of ciclosporin A in healthy volunteers. Methods Findings Exp Clin Pharmacol. 2006;28:25–29.
   PubMed Web of Science ®Google Scholar
• Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonate. 1993;63:201–208.
   PubMedGoogle Scholar
• Affuso F, Mercurio V, Fazio V, et al. Cardiovascular and metabolic effects of Berberine. World J Cardiol. 2010;2:71–77.
   PubMedGoogle Scholar
• Eng QY, Thanikachalam PV, Ramamurthy S. Molecular understanding of Epigallocatechin gallate (EGCG) in cardiovascular and metabolic diseases. J Ethnopharmacol. 2018;210:296–310.
   PubMed Web of Science ®Google Scholar
• Way T-D, Lin H-Y, Kuo D-H, et al. Pu-erh tea attenuates hyperlipogenesis and induces hepatoma cells growth arrest through activating AMP-activated protein kinase (AMPK) in human HepG2 cells. J Agric Food Chem. 2009;57:5257–5264.
   PubMed Web of Science ®Google Scholar
• Shishikura Y, Khokhar S, Murray BS. Effects of tea polyphenols on emulsification of olive oil in a small intestine model system. J Agric Food Chem. 2006;54:1906–1913.
   PubMed Web of Science ®Google Scholar
• Yuan F, Dong H, Fang K, et al. Effects of green tea on lipid metabolism in overweight or obese people: A meta-analysis of randomized controlled trials. Mol Nutr Food Res. 2018 Jan;62(1). doi: 10.1002/mnfr.201601122.7 Jun 21. [Epub ahead of print].
   Google Scholar
• Serban C, Sahebkar A, Antal D, et al. Effects of supplementation with green tea catechins on plasma C-reactive protein concentrations: a systematic review and meta-analysis of randomized controlled trials. Nutrition. 2015;31:1061–1071.
   PubMed Web of Science ®Google Scholar
• Park CS, Kim W, Woo JS, et al. Green tea consumption improves endothelial function but not circulating endothelial progenitor cells in patients with chronic renal failure. Int J Cardiol. 2010;145:261–262.
   PubMed Web of Science ®Google Scholar
• Zhang C, Qin -Y-Y, Wei X, et al. Tea consumption and risk of cardiovascular outcomes and total mortality: a systematic review and meta-analysis of prospective observational studies. Eur J Epidemiol. 2015;30:103–113.
   PubMed Web of Science ®Google Scholar
• Cicero AF, Fogacci F, Colletti A. Potential role of bioactive peptides in prevention and treatment of chronic diseases: a narrative review. Br J Pharmacol. 2017;174:1378–1394.
   PubMed Web of Science ®Google Scholar
• Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. Eur J Clin Nutr. 2003;57:940–946.
   PubMed Web of Science ®Google Scholar
• Tokede OA, Onabanjo TA, Yansane A, et al. Soya products and serum lipids: a meta-analysis of randomised controlled trials. Br J Nutr. 2015;114:831–843.
   PubMed Web of Science ®Google Scholar
• Beavers DP, Beavers KM, Miller M, et al. Exposure to isoflavone-containing soy products and endothelial function: a Bayesian meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2012;22:182–191.
   PubMed Web of Science ®Google Scholar
• Hazim S, Curtis PJ, Schär MY, et al. Acute benefits of the microbial-derived isoflavone metabolite equol on arterial stiffness in men prospectively recruited according to equol producer phenotype: a double-blind randomized controlled trial. Am J Clin Nutr. 2016;103:694–702.
   PubMed Web of Science ®Google Scholar
• EFSA Panel on Dietetic Products NaAN Scientific Opinion on the substantiation of health claims related to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and maintenance of normal cardiac function (ID 504, 506, 516, 527, 538, 703, 1128, 1317, 1324, 1325), maintenance of normal blood glucose concentrations (ID 566), maintenance of normal blood pressure (ID 506, 516, 703, 1317, 1324), maintenance of normal blood HDL-cholesterol concentrations (ID 506), maintenance of normal (fasting) blood concentrations of triglycerides (ID 506, 527, 538, 1317, 1324, 1325), maintenance of normal blood LDL-cholesterol concentrations (ID 527, 538, 1317, 1325, 4689), protection of the skin from photo-oxidative (UV-induced) damage (ID 530), improved absorption of EPA and DHA (ID 522, 523), contribution to the normal function of the immune system by decreasing the levels of eicosanoids, arachidonic acid-derived mediators and pro-inflammatory cytokines (ID 520, 2914), and “immunomodulating agent” (4690) pursuant to Article 13 (1)of Regulation (EC) No 1924/20061. EFSA J. 2010;8:1796–1828. 163.
   Google Scholar
• Howe P, Mori T, Buckley J. Long chain omega-3 fatty acids and cardiovascular disease – FSANZ consideration of a commissioned review. FSANZ. 2013. [cited 2017 Mar 31]. Available from: http://www.foodstandards.gov.au/consumer/labelling/nutrition/documents/FSANZ%20consideration%20of%20omega-3%20review1.pdf.
   Google Scholar
• Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17:387–393.
   PubMed Web of Science ®Google Scholar
• Eslick GD, Howe PR, Smith C, et al. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol. 2009;136:4–16.
   PubMed Web of Science ®Google Scholar
• Leslie MA, Cohen DJ, Liddle DM, et al. A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals. Lipids Health Dis. 2015;14:53.
   PubMed Web of Science ®Google Scholar
• Cicero AF, Reggi A, Parini A, et al. Application of polyunsaturated fatty acids in internal medicine: beyond the established cardiovascular effects. Arch Med Sci. 2012;8:784–793.
   PubMed Web of Science ®Google Scholar
• Cicero AF, Colletti A. Krill oil: evidence of a new source of polyunsaturated fatty acids with high bioavailability. Clin Lipidol. 2015;10:1–4.
   Web of Science ®Google Scholar
• Ursoniu S, Sahebkar A, Serban M-C, et al.; Lipid and Blood Pressure Meta-analysis Collaboration Group. Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2017;75:361–373.
   PubMed Web of Science ®Google Scholar
• Wachira JK, Larson MK, Harris WS. n-3 Fatty acids affect haemostasis but do not increase the risk of bleeding: clinical observations and mechanistic insights. Br J Nutr. 2014 May;111(9):1652–1662.
   PubMed Web of Science ®Google Scholar
• Serban M-C, Sahebkar A, Mikhailidis DP, et al. Impact of L-carnitine on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2016;6:19188.
   PubMed Web of Science ®Google Scholar
• Pooyandjoo M, Nouhi M, Shab-Bidar S, et al. The effect of (L-) carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2016;17:970–976. 207.
   PubMed Web of Science ®Google Scholar
• Mazidi M, Rezaie P, Banach M Impact of L-carnitine on C-reactive protein: a systematic review and meta-analysis of 10 randomized control trials with 925 patients. Presentation at 2nd CPPEI Congress in Vienna, July 2017 (data unpublished).
   Google Scholar
• Serban M-C, Sahebkar A, Dragan S, et al. A systematic review and meta-analysis of the impact of Spirulina supplementation on plasma lipid concentrations. Clin Nutr. 2016;35:842–851.
   PubMed Web of Science ®Google Scholar
• Neyrinck AM, Taminiau B, Walgrave H, et al. Spirulina protects against hepatic inflammation in aging: an effect related to the modulation of the gut microbiota? Nutrients. 2017;9(6):633.
   Web of Science ®Google Scholar
• Johnston TP, Korolenko TA, Pirro M, et al. Preventing cardiovascular heart disease: promising nutraceutical and non-nutraceutical treatments for cholesterol management. Pharmacol Res. 2017;120:219–225.
   PubMed Web of Science ®Google Scholar
• Cicero AF, Parini A, Rosticci M, et al. Nutraceuticals and cholesterol-lowering action. Int J Cardiol Met Endocr. 2015;6:1–4.
   Google Scholar
• Gonnelli S, Caffarelli C, Stolakis K, et al. Efficacy and tolerability of a nutraceutical combination (Red Yeast Rice, Policosanols, and Berberine) in patients with low-moderate risk hypercholesterolemia: a double-blind, placebo-controlled study. Curr Ther Res Clin Exp. 2014 Nov;15(77):1–6.
   Google Scholar
• Cicero AF, Colletti A. Combinations of phytomedicines with different lipid lowering activity for dyslipidemia management: the available clinical data. Phytomedicine. 2016;23(11):1113–1118.
   PubMed Web of Science ®Google Scholar
• Cicero AF, Colletti A. Statins and nutraceuticals/functional food: could they be combined?. In: Banach M, editor. Combination therapy in dyslipidemia. Springer Verlag; 2015. p. 127–142.
   Google Scholar
• Hunter PM, Hegele RA. Functional foods and dietary supplements for the management of dyslipidaemia. Nat Rev Endocrinol. 2017 May;13(5):278–288.
   PubMed Web of Science ®Google Scholar
• Somdat M, Yashwant VP. Nutraceuticals and health: review of human evidence. Nutraceut Basic Res Clin Appl. 2016.
   Google Scholar
• Dutta D, Pathak Y. Background to Nutraceuticals and Human Health. In: Mahabir  S, Pathak YV (Eds). Nutraceuticals and Health: Review of Human Evidence. CRC Press. 2016;3–18.
   Google Scholar